COMMUNIQUÉS West-GlobeNewswire

EssilorLuxottica acquires RetinAI, accelerating transformative AI and data-powered eye health solutions
15/10/2025
EssilorLuxottica acquires RetinAI, accelerating transformative AI and data-powered eye health solutions Paris, France (15 October 2025) – EssilorLuxottica announces the acquisition of Ikerian AG, a health technology [...]
EssilorLuxottica acquiert RetinAI, accélérant dans les solutions transformatrices de santé de l’œil portées par l'IA et la data
15/10/2025
EssilorLuxottica acquiert RetinAI, accélérant dans les solutions transformatrices de santé de l’œil portées par l'IA et la data Paris, France (15 octobre 2025) – EssilorLuxottica annonce l'acquisition d'Ikerian AG, une [...]
HC3 Named Exclusive U.S. Distributor of MICA Advance System for Rapid Legionella Detection
15/10/2025
Tallahassee, Florida, Oct. 15, 2025 (GLOBE NEWSWIRE) -- HC3 Health Care Consulting has officially been named the exclusive U.S. distributor and training provider for the MICA Advance Legionella system , a next- [...]
IPSEN - Buy-back programme - Art 5 of MAR - Week 41 - 2025
15/10/2025
Aggregated presentation by day and by market Statement of transactions in own shares from October 06th to October 10th 2025 Name of the issue Identity code of the issuer (Legal Entity Identifier) Day of the transaction [...]
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 41 - 2025
15/10/2025
Présentation agrégée par jour et par marché Déclaration des transactions sur actions propres réalisées du 06 Octobre au 10 Octobre 2025 Nom de l'émetteur Code identifiant de l'émetteur (code LEI) Jour de la transaction [...]
Consortium consisting of Nordic Capital and Permira increases offer price and extends offer period until 5 November 2025 in respect of the takeover offer to the shareholders of Bavarian Nordic
15/10/2025
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION COPENHAGEN, Denmark, [...]
Eascra Biotech Named to Fast Company’s “Next Big Things in Tech 2025”
15/10/2025
Recognition for groundbreaking work and pioneering space manufacturing BOSTON, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Fast Company has named Eascra Biotech, a nanomedicine startup, to its annual Next Big Things in Tech list [...]
Ketabon Presents New Data Showing Antidepressant Effects of Oral Ketamine (KET01) Are Independent of Dissociation
15/10/2025
Findings Presented at ECNP 2025 in Amsterdam Support the Potential for a Safe At-Home Treatment Option in Treatment-Resistant Depression MUNICH, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Ketabon GmbH (“Ketabon” or “the Company [...]
WeightWatchers for Business Annual Report Shows Breakthrough Weight Loss Results and Health Outcomes
15/10/2025
Members See 46% Improvement in Work-Related Quality of Life and 53% Improvement in Overall Quality of Life WeightWatchers Members Lost 21% of Their Body Weight, Outperforming Results by Other Telehealth Providers NEW [...]
Canada’s Largest Family Medicine Gathering Comes to Winnipeg This November
15/10/2025
Focused on advancing patient care through education, collaboration, and innovation Event Information: Family Medicine Forum November 5–8, 2025 (Winnipeg) fmf.cfpc.ca MISSISSAUGA, Ontario, Oct. 15, 2025 (GLOBE NEWSWIRE [...]
Le plus grand rassemblement de médecins de famille au pays posera ses valises à Winnipeg en novembre
15/10/2025
Centré sur l’amélioration des soins aux patients grâce à l’éducation, à la collaboration et à l’innovation Information sur l’événement : Forum en médecine familiale Du 5 au 8 novembre 2025 (Winnipeg) fmf.cfpc.ca/fr/ [...]
Evaluation of SON-1010 Using a Patient-Derived Tumoroid Platform to Support an Ongoing Phase 1 Study in Patients with Sarcoma
15/10/2025
HOUSTON, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) is collaborating with Spanios on a non-clinical study using New Alternate Methodologies (NAM)-based patient-derived tumoroid [...]
Baylor Genetics Presents New Data on Clinical and Diagnostic Utility of RNA Sequencing for Rare Disease at the American Society of Human Genetics 2025 Annual Meeting
15/10/2025
Research underscores clinical utility of RNA sequencing in providing critical insights to drive diagnoses and medical management HOUSTON, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Baylor Genetics , a clinical diagnostic [...]
Noom Introduces “Mindful Art Break” — A Weekly Practice Designed to Spark Awe, Relieve Stress, and Boost Psychological Wellbeing
15/10/2025
Noom open sources wellbeing by releasing its art-impact research, AI art-scoring tools, and the A.R.T. (Art Research Tool) into the public domain PRINCETON, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Noom , the leading [...]
BioRestorative Therapies to Participate in the 2025 Maxim Growth Summit
15/10/2025
MELVILLE, N.Y., Oct. 15, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and [...]
Biomerica Reports First Quarter Fiscal 2026 Financial Results
15/10/2025
Reported Improved Gross Margin from Contribution from Higher-Margin Product Mix Operating Expenses Continued to Decline Compared to the First Quarter of the Prior Fiscal Year, Reflecting the Company’s Ongoing Focus on [...]
Quercis Pharma and Thomas Lines Nominated for Prestigious Prix Galien USA “Best Startup” Award
15/10/2025
Recognition highlights company’s antithrombotic platform and late-stage programs designed to transform care in oncology and inflammation driven diseases ZUG, Switzerland, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Quercis Pharma [...]
Anteris Receives First European Regulatory Clearance to Commence DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)
15/10/2025
MINNEAPOLIS and BRISBANE, Australia, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ( Anteris or the Company ) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, [...]
Artelo Biosciences Announces Expanded Clinical Data to be Presented on both ART26.12 and ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit
15/10/2025
ART26.12 Phase 1 Data Demonstrated No Safety Concerns, Predictable Linear Plasma Exposure, and Options for Dosing in Either Fed or Fasted Conditions ART27.13 Interim Phase 2 Data Showed Substantial Weight Gain and [...]

Pages